The evidence-based clinical approach to HF treatment recommended in the American College of Cardiology/American Heart Association guidelines has led to a reduction in mortality over time, mostly related to the use of combinations of angiotensin-converting enzyme (ACE) inhibitors, beta blockers (BB), and mineralocorticoid receptor antagonists [5–8]. The gene discussed is ACE; the disease is hydrops fetalis.